• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Sor­ry No­vo: Sanofi wins Abl­ynx over with $4.8B buy­out bid, bag­ging nanobody plat­form tech

8 years ago
Deals

In post-IPO par­ty, Nas­daq’s new­com­ers Ar­mo, Men­lo and Sol­id soar with­in hours of list­ing

8 years ago
Financing
Pharma

No­var­tis scores a quick FDA OK for its new can­cer drug Lu­tathera, picked up in $4B buy­out

8 years ago
Pharma

Vas Narasimhan joins the pow­er cir­cle at Davos; Ar­mo Bio, resTOR­bio rais­es $128M and $85M in IPO

8 years ago
News Briefing

Hep­tares co-founder Fiona Mar­shall to lead Mer­ck­'s Lon­don re­search hub; Abl­ynx ap­points Robert Friesen as new CFO

8 years ago
Peer Review

Ex-Mer­ri­mack CEO Mul­roy launch­es on­col­o­gy start­up Part­ner Ther­a­peu­tics

8 years ago
Startups
Outsourcing

When will Bio­gen fi­nal­ly pull the trig­ger on a block­buster M&A deal?

8 years ago
Deals

Be­hind the deal spree, Cel­gene con­tin­ues to cau­tious­ly ex­plore neu­ro­sciences

8 years ago
R&D

Un­der pres­sure to per­form, Wood­ford coun­ter­at­tacks against Sahm Ad­rangi's lat­est short as­sault

8 years ago
Pharma

Trail­ing GSK, As­traZeneca of­fers an en­cour­ag­ing look at PhI­II da­ta for three-in-one COPD in­haler

8 years ago
R&D

Fast-grow­ing Shang­hai Phar­ma to plant foot in San Diego, hunt­ing deals in US and Eu­rope

8 years ago
China

Duchenne MD dad piv­ots from last-minute alert on FDA's par­tial hold to $125M IPO for Sol­id Bio

8 years ago
Financing

Sum­mit shares shoot up on pos­i­tive DMD PhII; As­traZeneca and al­lies back a new in­cu­ba­tor/ac­cel­er­a­tor at Babra­ham

8 years ago
News Briefing

Women’s health biotech KaNDy dick­er­ing with Al­ler­gan about a $400M buy­out deal — re­port

8 years ago
Deals

Men­lo bags $119M IPO on promise of ex-Mer­ck drug

8 years ago
Financing

Take­da and Zin­fan­del write off yet an­oth­er Alzheimer’s PhI­II af­ter Ac­tos fails a key in­ter­im test

8 years ago
R&D

Bio­gen makes a buy­out deal, but it’s not the big one you’ve been wait­ing for

8 years ago
Pharma

Eli Lil­ly fi­nal­ly pub­lished its dis­as­trous EX­PE­DI­TION3 da­ta, a cost­ly les­son in re­think­ing Alzheimer's

8 years ago
R&D

In a break­through, Chi­nese re­searchers clone mon­keys hop­ing to pro­vide bet­ter dis­ease mod­els

8 years ago
China

GW on fire: PhI­II epilep­sy da­ta sig­nals suc­cess ahead for first CBD drug

8 years ago
R&D

No­var­tis steps in to grab ex-US rights to pi­o­neer­ing gene ther­a­py Lux­tur­na with $170M deal

8 years ago
R&D
Pharma

Ex-Al­ler­gan team at Bon­ti rais­es $15.5M for an­oth­er neu­ro­tox­in; Shire com­mits to pub­lish­ing in open ac­cess jour­nals ...

8 years ago
News Briefing

The new se­r­i­al en­tre­pre­neur in the biotech are­na launch­es an­oth­er up­start look­ing to drug RNA

8 years ago
Startups

Pfiz­er’s lat­est copy­cat could put the squeeze on Roche — again

8 years ago
R&D
Pharma
First page Previous page 1054105510561057105810591060 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.